Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open …

…, S Harrow, S Gaede, AV Louie, C Haasbeek, L Mulroy… - The Lancet, 2019 - thelancet.com
Background The oligometastatic paradigm suggests that some patients with a limited number
of metastases might be cured if all lesions are eradicated. Evidence from randomised …

[HTML][HTML] Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial

…, AV Louie, C Haasbeek, L Mulroy… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …

[PDF][PDF] Randomized, double-blind, placebo-controlled trial of erythropoietin in non–small-cell lung cancer with disease-related anemia

…, C Smith, B Szechtman, W Roa, L Mulroy… - Journal of Clinical …, 2007 - researchgate.net
Purpose Previous trials have suggested a quality-of-life (QOL) improvement for anemic
cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We …

Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes

…, S Gaede, AV Louie, C Haasbeek, L Mulroy… - International Journal of …, 2022 - Elsevier
Purpose Long-term randomized data assessing the effect of ablative therapies in patients
with oligometastases are lacking. The Stereotactic Ablative Radiotherapy for the …

[HTML][HTML] Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase …

…, D Schellenberg, M Liu, S Gaede, J Laba, L Mulroy… - BMC cancer, 2019 - Springer
Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment
option for patients with oligometastatic disease. SABR delivers precise, high-dose, …

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC. 15)

…, C Grafton, C Lochrin, C Leong, L Mulroy… - International Journal of …, 2002 - Elsevier
Purpose : This multi-institutional Phase III randomized study compared 10 Gy single-fraction
radiotherapy (RT) with 20 Gy in five fractions in the palliation of thoracic symptoms from lung …

Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)

…, JG Smith, T Nijjar, JJ Biagi, LA Mulroy… - The lancet …, 2018 - thelancet.com
Background A short course of radiotherapy is commonly prescribed for palliative relief of
malignant dysphagia in patients with incurable oesophageal cancer. We compared …

Quality of life outcomes after stereotactic ablative radiation therapy (SABR) versus standard of care treatments in the oligometastatic setting: a secondary analysis of …

…, S Gaede, A Louie, C Haasbeek, L Mulroy… - International Journal of …, 2019 - Elsevier
Purpose Randomized data assessing the longitudinal quality of life (QoL) impact of stereotactic
ablative radiation therapy (SABR) in the oligometastatic setting are lacking. Methods and …

Is SABR cost-effective in oligometastatic cancer? An economic analysis of the SABR-COMET randomized trial

…, S Harrow, A John-Baptiste, S Gaede, LA Mulroy… - International Journal of …, 2021 - Elsevier
Purpose The phase 2 randomized study SABR-COMET demonstrated that in patients with
controlled primary tumors and 1 to 5 oligometastatic lesions, SABR was associated with …

Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus (PROACTIVE): a phase 3 randomized clinical trial

…, A Fairchild, A Bezjak, D Gopaul, L Mulroy… - JAMA …, 2022 - jamanetwork.com
Importance Palliative thoracic radiotherapy (RT) can alleviate local symptoms associated
with advanced non–small cell lung cancer (NSCLC), but esophagitis is a common treatment-…